Advertisement

Selective depletion of the allo-antigen specific T cells by Fas/FasL pathway by cytokine IFN-γ and IL-2

  • Xiao Juan
  • Zhou Ping
  • Liu Zhongwen
  • Liu Lingbo
  • Hu Zhongbo
Article
  • 29 Downloads

Summary

To investigate the value of apoptosis of the allo-antigen specific T cells induced by Fas/FasL pathway in preventing graft-versus-host disease (GVHD), the CD34+ cells transfected with FasL or not, used as stimulus cells, were mixed with allo-antigen specific T lymphocytes in presence or absence of IFN-γ and IL-2. After 5 days, apoptosis of T cells was detected by TdT nick end mediated dUTP labeling (TUNEL) and flow cytometry (FCM). The affects of these two cytokines on CD34+ cells in the graft were also compared. The ratio of apoptosis of T cells was 12.1±1.5% when CD34+ cells transfected with FasL was used as stimulus cells, much higher than that of CD34+ cells non-transfected (3.2±1.1%,P<0.01). And in presence of IFN-γ or IL-2, the ratio reached 20.1±2.3%, 17.6±1.3% respectively (P<0.01). However, IFN-γ up-regulated Fas expression of CD34+ cells and increased the sensibility of CD34+ cells to soluble FasL(sFasL); IL-2 showed no such affect. It is possible to induce apoptosis of the allo-antigen specific T cells of grafts activated by allo-antigen by exogenous Fas ligand expressed on recipient cells and this might provide a new approach for preventing GVHD and IL-2 may be more suitable for clinical application.

Key words

Fas ligand CD34+ cells T lymphocytes apoptosis graft-versus-host disease cytokine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kataoka Y, Iwasaki T, Kuroiwa Tet al. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology, 2001, 103: 310PubMedCrossRefGoogle Scholar
  2. 2.
    Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am, 1990, 4: 687PubMedGoogle Scholar
  3. 3.
    Connell J, Sullivan G C, Collins J Ket al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med, 1996, 184: 1075CrossRefGoogle Scholar
  4. 4.
    Lau H T, Yu M, Fontana Aet al. Prevetion of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science, 1996, 273: 109PubMedCrossRefGoogle Scholar
  5. 5.
    van den Brink M R, Moore E, Horndasch KJet al. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation, 2000, 70: 184PubMedGoogle Scholar
  6. 6.
    Deeg H J. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int J Hematol, 2001, 74(1):26PubMedCrossRefGoogle Scholar
  7. 7.
    Deeg H J, Beckham C, Loken M Ret al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma, 2000, 37: 405PubMedGoogle Scholar
  8. 8.
    Stahnke K, Hecker S, Kohne Eet al. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol, 1998, 26: 844PubMedGoogle Scholar

Copyright information

© Springer 2003

Authors and Affiliations

  • Xiao Juan
    • 1
  • Zhou Ping
    • 1
  • Liu Zhongwen
    • 1
  • Liu Lingbo
    • 1
  • Hu Zhongbo
    • 1
  1. 1.The Institute of Hematology, Xiehe Hospital, Tongji Medical CollegeHuazhong University of Science & TechnologyWuhan

Personalised recommendations